1. Hirsh J, Guyatt G, Albers GW, Harrington R, Schünemann HJ, American College of Chest Physicians: Executive summary: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest. 2008, 133 (Suppl): 71-109. 10.1378/chest.08-0693. Erratum in: Chest 2008;134:892, 8
2. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, American College of Chest Physicians: Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008, 133 (Suppl): 160-198. 10.1378/chest.08-0670.
3. XARELTO®(rivaroxaban) Product Monograph. [
http://www.bayer.ca/files/XARELTO-PM-ENG-10SEP2008-119111.pdf?#
]
4. Pradax™ (dabigatran) Product Monograph. [
http://www.boehringer-ingelheim.ca/content/dam/internet/opu/ca_EN/documents/humanhealth/product_monograph/Pradax-pm.pdf
]
5. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, the ROCKET AF Steering Committee for the ROCKET AF Investigators: Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 2011, [
http://www.nejm.org/doi/full/10.1056/NEJMoa1009638
]